NLS Pharmaceutics Announces Company Update on Strategic Partnerships
NLS Pharmaceutics to issue important update on strategic discussions and Phase 3 timeline
Positive
NLS Pharmaceutics plans to issue an important update on strategic partnerships and the timeline for its Phase 3 program in narcolepsy.
10/12/2023 - 09:40 AM
Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3, NLS to Webcast its Event Friday, October 20 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / October 12, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including Timeline for the company's Phase 3 program in narcolepsy
The event will be held October 20, 2023, at 11:00 am ET and may will include a video stream on the Investors section of the Company's website. A replay will be available on the NLS' website within 48 hours after the event.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com .
For additional information:
Marianne Lambertson (investors & media) ml@nls-pharma.com www.nlspharma.com
SOURCE: NLS Pharmaceutics AG
https://www.accesswire.com/792351/nls-pharmaceutics-announces-company-update-on-strategic-partnerships
What is the announcement about?
The announcement is about NLS Pharmaceutics providing an update on strategic partnerships and the timeline for its Phase 3 program in narcolepsy.
When will the event take place?
The event will be held on October 20, 2023, at 11:00 am ET.
Where can I watch the event?
The event may include a video stream on the Investors section of NLS Pharmaceutics' website.
Will there be a replay of the event?
Yes, a replay will be available on NLS Pharmaceutics' website within 48 hours after the event.
NLSP Rankings
#633 Ranked by Stock Gains
NLSP Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major
About NLSP
mission & values to serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. we value partnership and integrity, we are ethical and responsible and show respect and compassion for our patients. r&d strategy the successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. r&d is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. the advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. our innovative r&d is centered on patients’ needs and delivering affordable, safe and effective solutions. not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & developm
